In 691 adults followed for 80 weeks, higher doses roughly tripled the drop in nightly breathing pauses seen on placebo. The Lilly-funded results ran in NEJM, and the drug is still unapproved.
Recap by typeshit. Full story at health.
The Scientist weighs whether GLP-1 drugs could lengthen life and finds the answer still unsettled. Tap through for where the research stands.
The review covers 47 peptides from meat, leather and seafood waste and cites a 12-trial meta-analysis showing a systolic drop of about 5 mmHg, credited to the authors.
Researchers think orexin drugs could expand into ADHD and fatigue the way GLP-1s grew past diabetes. Alkermes reported early ADHD results in 50 adults.
Researchers report in Amino Acids that the peptide blocks HMGA2 at the IL6 promoter in a cell model. The authors note the work is cell culture only, far from any human use.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
Loading…